




<b>theranos</b>	<b>Theranos Ferritin (FRT) assay</b>	Document Number: CL-RPT-145007
	<b>Ferritin validation report</b>	Revision: A
		Effective Date: 1/17/2014
<b>Ferritin (FRT) Immunoassay Validation Report</b>		

**Author(s):**


Signature: 	Date: 2/18/2014
Name: Adam Rosendorff, MD	Title: Laboratory Director

**Reviewer(s)**

Signature: 	Date: 3/19/14
Name: Sharada Sivaraman, PhD	Title: Immunoassay Team Leader

Signature: 	Date: 3/18/2014
Name: Daniel Young, Ph.D.	Title: Vice President

**Approver(s):**

Signature: 	Date: 2/18/2014
Name: Adam Rosendorff, M.D	Title: Laboratory Director

 9/19/15

Sunil S. Dhawan M.D.

<b>theranos</b>	<b>Theranos Ferritin (FRT) assay</b>	Document Number:CL-RPT-145007
	<b>Ferritin validation report</b>	Revision: A
		Effective Date: 1/17/2014
<b>Ferritin (FRT) Immunoassay Validation Report</b>		

**TABLE OF CONTENT**

<b>1</b>	<b>ASSAY BACKGROUND .....</b>	<b>4</b>
<b>2</b>	<b>REGULATION AND GUIDANCE .....</b>	<b>4</b>
<b>3</b>	<b>PRINCIPLE OF THE PROCEDURE .....</b>	<b>4</b>
<b>4</b>	<b>CALIBRATION .....</b>	<b>5</b>
<b>5</b>	<b>QUALITY CONTROL .....</b>	<b>5</b>
<b>6</b>	<b>PRECISION .....</b>	<b>6-8</b>
<b>7</b>	<b>METHOD COMPARISON: THERANOS VERSUS PREDICATE .....</b>	<b>8-9</b>
<b>8</b>	<b>REFERENCE RANGE VERIFICATION .....</b>	<b>10-11</b>
<b>9</b>	<b>REFERENCES .....</b>	<b>12</b>

Theranos Internal  
 Only

<b>theranos</b>	<b>Theranos Ferritin (FRT) assay</b>	Document Number:CL-RPT-145007 Revision: A
	<b>Ferritin validation report</b>	Effective Date: 1/17/2014
<b>Ferritin (FRT) Immunoassay Validation Report</b>		

Theranos Internal  
Only

<b>theranos</b>	<b>Theranos Ferritin (FRT) assay</b>	Document Number:CL-RPT-145007 Revision: A
	<b>Ferritin validation report</b>	Effective Date: 1/17/2014
<b>Ferritin (FRT) Immunoassay Validation Report</b>		

## 1 ASSAY BACKGROUND

Ferritin is a 450 KDa protein complex consisting of 24 subunits, that form a shell, and is the primary intracellular iron storage molecule in eukaryotes. When fully bound by iron, it is estimated that over 20% of Ferritin protein consists of iron by weight. Denatured ferritin is called hemosiderin and ferritin without bound iron is known as apoferritin. Free iron is toxic to cells as it leads to the production of free radicals via the Fenton reaction. Ferritin binds iron and keeps it from producing free radicals. Measurements of ferritin may aid in the diagnosis of diseases affecting iron metabolism, such as hemochromatosis (iron overload) and iron deficiency anemia. Recent literature suggests that ferritin may decline before increases in TIBC and transferrin saturation, providing an earlier indication of iron deficiency. The combination of MCV and Ferritin may provide an extremely accurate method for discriminating beta-thalassemia (low MCV, normal ferritin) from iron deficiency anemia (low MCV, low ferritin).

## 2 REGULATION AND GUIDANCE

The qualification/validation of the ELISA assays on the Theranos device will be in accordance with C.F.R. Ch IV, § 493.1253 "Standard: Establishment and verification of performance specifications" and outlined in CLSI guideline C28A3.

## 3 PRINCIPLE OF THE TEST

In the ADVIA Chemistry Ferritin (FRT) assay, sample is diluted and reacted with a buffer that contains latex particles coated with antibody specific for ferritin. The formation of the antibody-antigen complex during the reaction results in an increase in turbidity, the extent of which is measured as the amount of light absorbed at 658 nm. By constructing a standard curve from the absorbance of standards, ferritin concentration of a sample can be determined.

Plasma samples were diluted 3.125 fold in saline prior to analysis.

<b>theranos</b>	<b>Theranos Ferritin (FRT) assay</b>	Document Number:CL-RPT-145007 Revision: A
	<b>Ferritin validation report</b>	Effective Date: 1/17/2014
<b>Ferritin (FRT) Immunoassay Validation Report</b>		

#### 4 CALIBRATION

4.1 In 42 CFR Part 493.1255, it is required to perform calibration procedures with at least the frequency recommended by the manufacturer, or using criteria specified by the laboratory, or when calibration verification fails to meet acceptable limits.

4.1.1 The term "calibration verification," as used in CLIA, includes:

4.1.1.1 Confirming that a calibration meets the method manufacturer's specifications

4.1.1.2 Verifying that the calibration is suitable for the entire measuring interval (or "reportable range," which is the CLIA term)

4.2 Calibrators were diluted 3.125 fold and verified on the ADVIA system

4.2.1 This dilution factor is within the acceptable limits of the ADVIA internal calibration test.

4.3 For the purposes of this Validation Plan, calibration was carried out with every new lot of reagents.

4.3.1 Each level was tested in replicates of 3 and the average was used to create a standard curve for testing.

4.3.2 The calibration was verified using quality controls.

#### 5 QUALITY CONTROL

5.1 Two to four level quality control samples, as appropriate to the assay, were analyzed with each calibration and before each test during the validation.

5.1.1 High = 29.7 ng/mL

5.1.2 Mid = 195 ng/mL

5.1.3 Low = 329 ng/mL

5.2 The QC levels are not included when generating the calibration curve.

<b>theranos</b>	<b>Theranos Ferritin (FRT) assay</b>	Document Number:CL-RPT-145007
	<b>Ferritin validation report</b>	Revision: A
		Effective Date: 1/17/2014
<b>Ferritin (FRT) Immunoassay Validation Report</b>		

## 6 PRECISION

6.1 Precision was evaluated according to CLSI standard EP5-A2, Evaluation of Precision Performance of Quantitative Measurement Methods.

6.1.1 A total of 20 runs were performed over 10 days with 2 runs per day and 2 replicates per run for a total of 40 data points. The following tables indicate the between-run, between-day and within-laboratory precision at 3 levels (29.7 ng/mL, 195 ng/mL and 329 ng/mL):

**Table I: Precision at 3 decision levels**

**Precision**

*CLSI guideline EP05-A2 section 10.8*

**Level = L1**

Number of observations	40
Number of runs	20
Number of days	10
Runs per day	2
Replicates per run	2

CLSI guideline EP05-A2 section 10.4 recommends a minimum of 40 runs, with 2 replicates per run.

Mean	29.09			
	SD	95% CI	CV	Allowable Total SD
Repeatability	0.63	0.48 to 0.90	2.2%	-
Between-run	0.33		1.1%	-
Between-day	0.46		1.6%	-
Within-laboratory	0.84	0.67 to 1.15	2.9%	7.27

Imprecision is less than allowable total imprecision: 25%.

**Level = L2**

Number of observations	40
Number of runs	20
Number of days	10
Runs per day	2
Replicates per run	2

CLSI guideline EP05-A2 section 10.4 recommends a minimum of 40 runs, with 2 replicates per run.

Mean	163.51			
	SD	95% CI	CV	Allowable Total SD
Repeatability	0.72	0.55 to 1.05	0.4%	-
Between-run	0.35		0.2%	-
Between-day	1.21		0.7%	-
Within-laboratory	1.46	1.07 to 2.29	0.9%	40.88

Imprecision is less than allowable total imprecision: 25%.

<b>theranos</b>	<b>Theranos Ferritin (FRT) assay</b>	Document Number:CL-RPT-145007
	<b>Ferritin validation report</b>	Revision: A
		Effective Date: 1/17/2014
<b>Ferritin (FRT) Immunoassay Validation Report</b>		

Level = L3

Number of observations	40
Number of runs	20
Number of days	10
Runs per day	2
Replicates per run	2

CLSI guideline EP05-A2 section 10.4 recommends a minimum of 40 runs, with 2 replicates per run.

Mean	SD	95% CI	CV	Allowable Total SD
273.28				
Repeatability	1.06	0.81 to 1.53	0.4%	-
Between-run	3.84		1.4%	-
Between-day	4.95		1.8%	-
Within-laboratory	6.35	4.63 to 10.12	2.3%	68.32

Imprecision is less than allowable total imprecision: 25%.

6.2 The mean recovery of controls 1, 2 and 3 versus the assigned values was as follows:

<u>Control#</u>	<u>Assigned (ng/mL)</u>	<u>Theranos (ng/mL)</u>	<u>% Recovery</u>
1	29.7	29.9	100.7%
2	195	163.5	83.8%
3	329	273.3	83.1%

6.3 Acceptance criteria:

Total allowable error (TAE %) of 25%, was selected as the acceptance criteria for this assay following CLIA proficiency guidelines as printed in the Federal Register February 28, 1992;57(40):7002-186, as well as published acceptance criteria published in the American Proficiency Institute Peer Data for 2013 CHEMISTRY / IMMUNOLOGY / IMMUNOHEM -1ST EVENT. Allowable bias was calculated as the residual error budget after precision values (CV %) were subtracted from TAE (%). Values in brackets indicate the closest/corresponding API levels obtained from 2013 proficiency data.

Bias was calculated by comparing the average Level 1, Level 2 and Level 3 QC values obtained with the Theranos values, versus the average values assigned to each Level by the predicate method (n=6 measurements for each level, section 6.2)

<b>theranos</b>	<b>Theranos Ferritin (FRT) assay</b>	Document Number:CL-RPT-145007 Revision: A
	<b>Ferritin validation report</b>	Effective Date: 1/17/2014
<b>Ferritin (FRT) Immunoassay Validation Report</b>		

Table II

	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
CV%	2.9	0.9	2.3
Bias%	0.7	16.2	16.9
TAE%	25	25	25
Allowable Bias (%)	22.1	24.1	22.7

For each level allowable bias exceeds observed bias therefore the TAE criteria are satisfied.

## 7 METHOD COMPARISON, THERANOS VERSUS PREDICATE

- 7.1 Because the ADVIA system allows users to extend the reportable range, a pre-dilution of sample is valid, and the volume of sample obtained from a fingerstick is sufficient for testing on the system. To verify the comparability of fingerstick blood to venous blood, 20 unique patients donated 2 venous tubes of blood and 2-4 fingerstick samples in EDTA. Each sample of venous blood was tested and the 2 results were used as replicate tests. Fingerstick samples were pooled and tested in replicates of 2. All samples should be within the reference range, and were also subject to the reference range criteria.
- 7.2 Calculated concentrations are based on the mean of 2 replicate tests.
- 7.3 Acceptance Criteria:
- 7.3.1 All samples must have %CV within 20%
- 7.3.2 Scatter plots should have a slope of 1 +/- 0.15 and R<sup>2</sup> greater than 0.9
- 7.3.3 Regression equation for CTN versus matched venous samples is shown below and passes acceptance criteria.

### Figure 2 Venous versus Fingerstick comparison





Theranos Ferritin (FRT) assay


Document Number:CL-RPT-145007

Revision: A

Ferritin validation report

Effective Date: 1/17/2014

Ferritin (FRT) Immunoassay Validation Report



Theranos Internal  
Theranos Only

<b>theranos</b>	<b>Theranos Ferritin (FRT) assay</b>	Document Number:CL-RPT-145007
	<b>Ferritin validation report</b>	Revision: A
		Effective Date: 1/17/2014
<b>Ferritin (FRT) Immunoassay Validation Report</b>		

## 8 REFERENCE RANGE VERIFICATION

- 8.1 20 unique venous and matched CTN samples were collected and assayed in duplicate using the predicate and Theranos methods, and the average value was calculated. All samples were collected in EDTA, therefore to verify the published Siemens reference range that was established using Lithium-Heparin plasma, both venous and CTN values were transformed to normalized values according to the regression equation established in Section 7 ( $y (FS) = 0.9644x (CTN) + 4.4704$ )
- 8.2 Of the 20 values obtained, 19 (95%) fell within the Siemens published reference range, pooling male and female ranges: (5-148 ng/mL (F) and 28-365 ng/mL (M), into one range (5-365 ng/mL) for the purposes of the validation.
- 8.3 The RR is therefore verified (CLSI guidance C28-A3c).
- 8.4 Raw data for reference range verification is shown below:

Donor	Rep	CTN	Column1
16	1	6.3	6.55
	2	6.8	
19	1	9.4	9.9
	2	10.4	
	2	17.8	17.8
1	1	17.8	
5	1	23.5	23.55
	2	23.6	
	2	27.5	27.5
17	1	27.5	
3	1	30.8	31.15
	2	31.5	
8	1	38.8	38.95
	2	39.1	
13	1	40.3	40.7

<b>theranos</b>	<b>Theranos Ferritin (FRT) assay</b>	Document Number:CL-RPT-145007
	<b>Ferritin validation report</b>	Revision: A
		Effective Date: 1/17/2014
<b>Ferritin (FRT) Immunoassay Validation Report</b>		

	2	41.1	
14	1	48.6	49.05
	2	49.5	
18	1	54.2	54.25
	2	54.3	
12	1	74	74.5
	2	75	
10	1	80.6	80.65
	2	80.7	
6	1	90.5	90.9
	2	91.3	
	2	91.8	91.85
11	1	91.9	
20	1	98.4	99.1
	2	99.8	
	2	103.2	103.3
7	1	103.4	
2	1	126.4	126.45
	2	126.5	
9	1	135.6	135.6
	2	135.6	
15	1	145.8	146.7
	2	147.6	
4	1	441.5	445.95
	2	450.4	

Theranos Internal Only

<b>theranos</b>	<b>Theranos Ferritin (FRT) assay</b>	Document Number:CL-RPT-145007 Revision: A
	<b>Ferritin validation report</b>	Effective Date: 1/17/2014
<b>Ferritin (FRT) Immunoassay Validation Report</b>		

## 9 REFERENCES

- 9.1 Code of Federal Regulations, Title 42, Chapter IV, Subchapter G, Part 493, Subpart K, Sections 493.1217, 493.1253, and 493.1255.
- 9.2 DeSilva B, Smith W, Weiner R, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. *Pharmaceutical Res.* 2003; 20:1885-1900.
- 9.3 Guidance for Industry: bioanalytical method validation / U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2001.
- 9.4 R (version 2.13.1). The R Foundation for Statistical Computing, 07/08/2011.
- 9.5 StatisPro (version 1.13.00). Clinical and Laboratory and Standards Institute, Wayne, PA. 07/14/2011.
- 9.6 Dexter-Immunoassay (version 1.0), Theranos, Inc., 2009.
- 9.7 EP10-A3, Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures; Approved Guideline—Third Edition, 2006, Clinical and Laboratory Standards Institute, Wayne, PA.
- 9.8 EP15-A2, User Verification of Performance for Precision and Trueness; Approved Guideline—Second Edition. 2005, Clinical and Laboratory Standards Institute, Wayne, PA.
- 9.9 EP09-A2-IR, Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline—Second Edition (Interim Revision), 2010, Clinical and Laboratory Standards Institute, Wayne, PA.
- 9.10 EP05-A2, Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline—Second Edition, 2004, Clinical and Laboratory Standards Institute, Wayne, PA.
- 9.11 EP06-A, Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline, 2003, Clinical and Laboratory Standards Institute, Wayne, PA.
- 9.12 EP7-A2, Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition, 2004, Clinical and Laboratory Standards Institute, Wayne, PA.

<b>theranos</b>	<b>Theranos Ferritin (FRT) assay</b>	Document Number:CL-RPT-145007 Revision: A
	<b>Ferritin validation report</b>	Effective Date: 1/17/2014
<b>Ferritin (FRT) Immunoassay Validation Report</b>		

**Theranos Internal  
Only**